Abu Dhabi, UAE – The Abu Dhabi Stem Cell Center has created a qualitative medical achievement, represented by the development of an advanced immune treatment for multiple sclerosis in the Middle East.
This was based on the Therox platform for phototherapy, which was approved by the Department of Health – Abu Dhabi.
To constitute a pioneering step that consolidates the country’s position in medical innovation.
For the first time in the world, the first clinical trials applying extracorporeal photosensitivity (ECP) therapy to patients with multiple sclerosis have been successfully completed, opening the door to an innovative treatment option for this complex neurological disease in which the immune system attacks the nervous system, causing difficulties in movement, balance and speech.
This makes ECP treatment a new glimmer of hope, especially for patients for whom conventional treatments no longer provide the desired response.
Extracorporeal photosensitivity therapy is traditionally used to treat graft-versus-host disease and skin T-cell cancer.
However, the Abu Dhabi Stem Cell Center has expanded its use to include neuroimmune disorders.
It relied on a technique that removes white blood cells from the patient, activates them optically outside the body, and then returns them to him with the aim of restoring balance to the immune system.
This may contribute to slowing the progression of the disease and reducing the severity of its symptoms.
The National Multiple Sclerosis Society (NMSS) has been a supporting element in the progress of this research by providing the necessary funding to accelerate and expand the scope of the study.
Through its research grant programs, the Society continues to support pioneering studies such as the PHOMS study.
Which contributes to deepening scientific understanding, improving the level of care, and accelerating progress for the multiple sclerosis patient community.
